TY - JOUR
T1 - KDIGO Controversies Conference on onco-nephrology
T2 - kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
AU - Conference Participants
AU - Małyszko, Jolanta
AU - Bamias, Aristotelis
AU - Danesh, Farhad R.
AU - Dębska-Ślizień, Alicja
AU - Gallieni, Maurizio
AU - Gertz, Morie A.
AU - Kielstein, Jan T.
AU - Tesarova, Petra
AU - Wong, Germaine
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Porta, Camillo
AU - Abu-Alfa, Ali K.
AU - Amer, Hatem
AU - Beutel, Gernot
AU - Chapman, Jeremy
AU - Chen, Xiaohong
AU - Chudek, Jerzy
AU - Cosmai, Laura
AU - Danesi, Romano
AU - De Stefano, Filippo
AU - Iseki, Kunitoshi
AU - Jaimes, Edgar A.
AU - Jhaveri, Kenar D.
AU - Jurczyszyn, Artur
AU - Kazancioğlu, Rümeyza
AU - Kitchlu, Abhijat
AU - Kollmannsberger, Christian
AU - Lahoti, Amit
AU - Li, Yang
AU - Macía, Manuel
AU - Matsubara, Takeshi
AU - Mitropoulos, Dionysios
AU - Noiri, Eisei
AU - Perazella, Mark A.
AU - Ronco, Pierre
AU - Rosner, Mitchell H.
AU - Soler Romeo, Maria Jose
AU - Sprangers, Ben
AU - Stadler, Walter M.
AU - Stevens, Paul E.
AU - Tesař, Vladimír
AU - Torres da Costa e Silva, Verônica
AU - Vesole, David H.
AU - Vijayan, Anitha
AU - Viklický, Ondřej
AU - Workeneh, Biruh T.
AU - Yanagita, Motoko
AU - Zakharova, Elena
N1 - Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Amgen , Akebia Therapeutics, Boehringer Ingelheim, Fresenius Medical Care , GE Healthcare , and MediBeacon. We thank Jennifer King, PhD, for assistance with manuscript preparation. The conference agenda, discussion questions, and plenary session presentations are available on the KDIGO website: https://kdigo.org/conferences/onco-nephrology-conference/ .
Funding Information:
JM declared having consultancy fees from Fresenius Medical Care and Vifor Pharma. AB declared having received consultancy fees from BMS, Merck Sharp & Dohme (MSD), Pfizer, and Roche; speaker honoraria from Bristol Myers Squibb (BMS) and MSD; and research support from BMS and Pfizer. FRD declared having received research support from National Institutes of Health. MG declared having received speaker honoraria from General Electric. MAG declared having received consultancy fees from Abbvie, Alnylam, Amgen, Annexon, Appellis, Celgene, Janssen, Medscape, Physicians' Education Resource, Prothena, Research to Practice, Sanofi, and Spectrum; stock options from Aurora Bio; speaker honoraria from Akcea, Johnson and Johnson, and Teva; and research support from National Institutes of Health and Spectrum. JTK declared having received consultancy fees from Amgen and Vifor Pharma; stock from Chemocentryx; speaker honoraria from ExThera Medical and Vifor Pharma; and grants from ExThera Medical; and JTK was an expert witness in vaccine injury cases trialed at the US Federal Court of Claims. PT declared having received consultancy fees from AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, and Roche; and speaker honoraria from AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, and Roche. GW declared having received research support from the National Health and Medical Research Council. DCW declared having received consultancy fees from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mundipharma, Napp, and Vifor Fresenius Medical Care Renal Pharma; and speaker's honoraria from Amgen, Astellas, AstraZeneca, Mundipharma, Napp, Pharmacosmos, and Vifor Fresenius Medical Care Renal Pharma. WCW declared having consultancy fees from Akebia, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. CP declared having consultancy fees from AstraZeneca, BMS, Eisai, EUSA, Ipsen, Merck Serono, MSD, Novartis, and Pfizer; stock from DNA; and research support from AstraZeneca, BMS, Eisai, EUSA, GE, Ipsen, Merck Serono, MSD, Novartis, and Pfizer; and CP was an expert witness for DNA. All the other authors declared no competing interests.
Publisher Copyright:
© 2020 Kidney Disease: Improving Global Outcomes (KDIGO)
PY - 2020/12
Y1 - 2020/12
N2 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed.
AB - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed.
KW - chemotherapy
KW - chronic kidney disease
KW - kidney transplantation
KW - oncology
KW - tumor lysis syndrome
UR - http://www.scopus.com/inward/record.url?scp=85097311110&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.07.012
DO - 10.1016/j.kint.2020.07.012
M3 - Article
C2 - 33276867
AN - SCOPUS:85097311110
SN - 0085-2538
VL - 98
SP - 1407
EP - 1418
JO - Kidney International
JF - Kidney International
IS - 6
ER -